IBDEI1OL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,26871,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,26872,0)
 ;;=G25.79^^110^1293^9
 ;;^UTILITY(U,$J,358.3,26872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26872,1,3,0)
 ;;=3^Medication-Induced Movement Disorder,Other
 ;;^UTILITY(U,$J,358.3,26872,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,26872,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,26873,0)
 ;;=T43.205A^^110^1293^4
 ;;^UTILITY(U,$J,358.3,26873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26873,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,26873,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,26873,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,26874,0)
 ;;=T43.205D^^110^1293^5
 ;;^UTILITY(U,$J,358.3,26874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26874,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,26874,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,26874,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,26875,0)
 ;;=T43.205S^^110^1293^6
 ;;^UTILITY(U,$J,358.3,26875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26875,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,26875,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,26875,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,26876,0)
 ;;=G25.71^^110^1293^7
 ;;^UTILITY(U,$J,358.3,26876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26876,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,26876,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,26876,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,26877,0)
 ;;=G24.02^^110^1293^8
 ;;^UTILITY(U,$J,358.3,26877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26877,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,26877,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,26877,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,26878,0)
 ;;=G21.0^^110^1293^12
 ;;^UTILITY(U,$J,358.3,26878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26878,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,26878,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,26878,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,26879,0)
 ;;=T50.905A^^110^1293^1
 ;;^UTILITY(U,$J,358.3,26879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26879,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Init Encntr
 ;;^UTILITY(U,$J,358.3,26879,1,4,0)
 ;;=4^T50.905A
 ;;^UTILITY(U,$J,358.3,26879,2)
 ;;=^5052160
 ;;^UTILITY(U,$J,358.3,26880,0)
 ;;=T50.905S^^110^1293^2
 ;;^UTILITY(U,$J,358.3,26880,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26880,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Sequela
 ;;^UTILITY(U,$J,358.3,26880,1,4,0)
 ;;=4^T50.905S
 ;;^UTILITY(U,$J,358.3,26880,2)
 ;;=^5052162
 ;;^UTILITY(U,$J,358.3,26881,0)
 ;;=T50.905D^^110^1293^3
 ;;^UTILITY(U,$J,358.3,26881,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26881,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,26881,1,4,0)
 ;;=4^T50.905D
 ;;^UTILITY(U,$J,358.3,26881,2)
 ;;=^5052161
 ;;^UTILITY(U,$J,358.3,26882,0)
 ;;=F45.22^^110^1294^1
 ;;^UTILITY(U,$J,358.3,26882,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26882,1,3,0)
 ;;=3^Body Dysmorphic D/O
 ;;^UTILITY(U,$J,358.3,26882,1,4,0)
 ;;=4^F45.22
 ;;^UTILITY(U,$J,358.3,26882,2)
 ;;=^5003588
 ;;^UTILITY(U,$J,358.3,26883,0)
 ;;=F63.3^^110^1294^8
 ;;^UTILITY(U,$J,358.3,26883,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,26883,1,3,0)
 ;;=3^Trichotillomania (Hair-Pulling D/O)
